Background: Mutations in breast cancer susceptibility genes (BRCA1 and BRCA2) are
associated with increased risks for breast, ovarian, and other types of cancer. Purpose: To …

Importance Pathogenic mutations in breast cancer susceptibility
genesBRCA1andBRCA2increase risks for breast, ovarian, fallopian tube, and peritoneal …

Purpose To review new evidence on the benefits and harms of risk assessment, genetic
counseling, and genetic testing for BRCA-related cancer in women for the US Preventive …

Background: Clinically significant mutations of BRCA1 and BRCA2 genes are associated
with increased susceptibility for breast and ovarian cancer. Although these mutations are …

Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes
(BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and …

Description: Update of the 2005 US Preventive Services Task Force (USPSTF)
recommendation on genetic risk assessment and BRCA mutation testing for breast and …

For women in the United States, BRCA1/2 mutations occur in approximately 1 in 300 to 500
women. Risk of ovarian, fallopian, and peritoneal cancer is also increased to 39% in those …

Objective: Women who are carriers of BRCA gene mutations have an elevated lifetime risk
of developing breast or ovarian cancer. Although a number of risk-reducing options are …

Women with a germline BRCA1 or BRCA2 mutation or a hereditary predisposition for breast
and ovarian cancer have substantial risk of breast or ovarian cancer relative to the general …

Objective.—To provide recommendations for cancer surveillance and risk reduction for
individuals carrying mutations in theBRCA1orBRCA2genes. Participants.—A task force with …